Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy

MLA

C. Robert, et al. “Presence of Frequent Underlying RAS Mutations in Cutaneous Squamous Cell Carcinomas and Keratoacanthomas (CuSCC/KA) That Develop in Patients during Vemurafenib Therapy.” Journal of Clinical Oncology, vol. 29, May 2011, p. 8520. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f2ac2dcff82c1e1bac97e49f11414051&authtype=sso&custid=ns315887.

APA

C. Robert, J. A. Sosman, Kerstin Trunzer, Andrew K. Joe, James L. Troy, Grant A. McArthur, I. Puzanov, Axel Hauschild, Astrid Koehler, Olivia Spleiss, Dirk Schadendorf, W. Wu, Keith T. Flaherty, Mario E. Lacouture, Madeleine Duvic, A. Ribas, Paul B. Chapman, K. B. Kim, & K. B. Nolop. (2011). Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. Journal of Clinical Oncology, 29, 8520.

Chicago

C. Robert, J. A. Sosman, Kerstin Trunzer, Andrew K. Joe, James L. Troy, Grant A. McArthur, I. Puzanov, et al. 2011. “Presence of Frequent Underlying RAS Mutations in Cutaneous Squamous Cell Carcinomas and Keratoacanthomas (CuSCC/KA) That Develop in Patients during Vemurafenib Therapy.” Journal of Clinical Oncology 29 (May): 8520. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f2ac2dcff82c1e1bac97e49f11414051&authtype=sso&custid=ns315887.